Public health officials must characterize and estimate the magnitude of the risk, which involves considering both the likelihood that infection might occur in various circumstances, and the costs and benefits associated with each of the possible uncertain outcomes.
The CDC's newly established emerging infectious disease program would also provide valuable information. The Committee found cause for concern when it evaluated the FDA's actions in protecting the public from HIV in the nation's blood supply during the s.
Communication to Physicians and Patients One of the crucial elements of the system for collecting blood and distributing blood products to patients is the means by which to convey concern about the risks inherent in blood products.
Once there is an action plan, the Secretary of Health and Human Services must hold the agency leaders accountable for enforcing cooperation in implementing the plan. For example, following the introduction of effective antiretroviral therapy ART in the mids, surveillance requirements expanded to include the extent to which providers prescribe ART as indicated, patient adherence to ART, and met and unmet need for care given the demand on the health care system to treat a growing number of people living with HIV McNaghten et al.
No regulatory process should have its information base effectively controlled by an advisory panel. The vaccine did produce strong antibody responses to a region of the HIV surface protein.
In the face of scientific uncertainty, the PHS needs a series of criteria or triggers for taking regulatory or other public health actions to protect the safety of blood and blood products.
Also, further studies may be needed to check that vaccines effective in one clinical trial show similar efficacy in other populations. In addition, agencies need to monitor more systematically the long-term outcomes of blood transfusion and blood product infusion and to think far ahead to anticipate both new technologies and new threats to the safety of the blood supply.
The shield laws have made it difficult, and often impossible, to obtain compensation for HIV infection acquired from blood or blood products. In1, people were diagnosed.